Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06765668 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06765668 · ClinicalTrials.gov record · last posted 2025-08-24

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

StatusRecruiting
PhasePhase 4
Started2025-02-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 24, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

Amendment record 5 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 5 times since 2025-01-03; most recent amendment 2025-08-22. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-04-14
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06765668
Lead Sponsor Impax Laboratories, LLC
Collaborators: Amneal Pharmaceuticals, LLC
Conditions Parkinson Disease
Enrollment 220 participants
Start Date 2025-02-12
Primary Completion 2025-11 (estimated)
Study Completion 2026-08-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-24